UnknownNot Applicable

Rheopheresis for Raynaud's and Digital Ulcers in Systemic Sclerosis

Germany30 participantsStarted 2022-02-28

Plain-language summary

In this feasibility study, we aim to explore therapeutic Rheopheresis (RheoP) as a novel treatment option for SSc-associated Raynaud's phenomenon and/or digital ulcers and compare it to the standard of care treatment (intravenous iloprost. RheoP has been used for RP/DU with some success in observational studies, nevertheless, the optimal treatment modality, duration, or frequency of RheoP (and PEX in general) in SSc has not been established as of yet.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Adult patients fulfilling ACR/EULAR classification criteria for SSc
✓. Presence of RP with or without DU
✓. Failure of at least one standard of care treatment (CCB or iloprost) for at least three months
✓. RCS \> 4
✓. Possibility to obtain venous access (either through a peripherally or centrally inserted catheter)

Exclusion criteria

✕. Significant anemia (\<8 g/dL)
✕. Clinically relevant hemorrhagic diathesis or coagulopathy
✕. Diabetes mellitus
✕. Serious acute or chronic kidney (eGFR\<30 ml/min/1.73m2) or liver failure
✕. Hypotension with systolic blood pressure \<100 mmHg
✕. Chronic viral infections (HIV, Hepatitis B, C)
✕. Epilepsia, psychosis, dementia, or other relevant neurologic condition precluding the conduct of plasmapheresis
✕. Malignant disease or any other condition with life expectancy \<12 months

What they're measuring

Raynaud Condition Score (RCS)

Timeframe: 24 weeks

Trial details

NCT IDNCT05204784

SponsorPeter Korsten

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2023-12

Contact for this trial

Peter Korsten, Dr. med.

+49-551-39-60400 peter.korsten@med.uni-goettingen.de

View on ClinicalTrials.gov More Systemic Sclerosis trials